Code Waechter LLC Sells 315 Shares of Johnson & Johnson $JNJ

Code Waechter LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.9% in the 2nd quarter, Holdings Channel reports. The firm owned 4,231 shares of the company’s stock after selling 315 shares during the quarter. Code Waechter LLC’s holdings in Johnson & Johnson were worth $646,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Vanguard Group Inc. raised its position in Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock worth $38,800,371,000 after purchasing an additional 1,170,120 shares during the last quarter. Northern Trust Corp raised its position in Johnson & Johnson by 0.4% during the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock worth $5,131,723,000 after purchasing an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp raised its position in Johnson & Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after purchasing an additional 620,039 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 3.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after purchasing an additional 712,181 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock worth $3,031,955,000 after acquiring an additional 448,666 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $186.24 on Tuesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The firm has a market capitalization of $448.71 billion, a price-to-earnings ratio of 17.98, a PEG ratio of 2.19 and a beta of 0.40. The business has a 50-day simple moving average of $183.43 and a 200 day simple moving average of $167.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on JNJ. HSBC lifted their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. UBS Group lifted their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Barclays lifted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Finally, Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.